Yelamali AR, Chendamarai E, Ritchey JK, Rettig MP, DiPersio JF, Persaud SP (2025) Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning. Blood ICT 1(3):100012. doi: 10.1016/j.bict.2025.100012 PMID: 41574174
Objective: To develop and validate a modular streptavidin based antibody drug conjugate platform for optimizing antibody mediated hematopoietic stem cell transplant conditioning.
Summary: The authors demonstrate that a streptavidin drug conjugate system enables rapid comparison of antibody payload combinations for hematopoietic stem cell depletion and leukemia targeting. The study builds on prior work using CD45 targeted immunotoxins to achieve effective hematopoietic niche depletion in murine HSCT models.
Usage: This study references earlier conditioning experiments that utilized Streptavidin-ZAP (IT-27) in combination with biotinylated CD45 antibodies to selectively deplete hematopoietic stem cells in murine HSCT models, typically administered as a single intravenous dose of approximately 75 µg per mouse.
Related Products: Streptavidin-ZAP (Cat. #IT-27), Anti-CD45.2-SAP (Cat. #IT-91)